Evidence map›Paper›PMID 33808910›Full record

ArticleMolecules (Basel, Switzerland)2021

Towards Enhanced MRI Performance of Tumor-Specific Dimeric Phenylboronic Contrast Agents.

Jonathan Martinelli, Lorenzo Tei, Simonetta Geninatti Crich, Diego Alberti, Kristina Djanashvili

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022
    Review
  4. A Gadolinium DO3A AmideBiomedicines · 2021
    Article
  5. Rigid and Compact Binuclear Bis-hydrated Gd-complexes as High Relaxivity MRI Agents.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Jonathan MartinelliDepartment of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands.ORCID 0000-0001-5386-9015
Lorenzo TeiDepartment of Science and Technological Innovation, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.ORCID 0000-0002-7027-8396
Simonetta Geninatti CrichDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy.ORCID 0000-0003-2998-5424
Diego AlbertiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy.
Kristina DjanashviliDepartment of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands.ORCID 0000-0003-1511-015X
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Turin · ITDelft University of Technology · NL

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 722.012.009
6 · The paper itself

Abstract

It is known that phenylboronic acid (PBA) can target tumor tissues by binding to sialic acid, a substrate overexpressed by cancer cells. This capability has previously been explored in the design of targeting diagnostic probes such as Gd- and

Indexed as

Boronic AcidsContrast MediaMagnetic Resonance ImagingMelanoma, ExperimentalAnimalsCell Line, TumorMicebenzeneboronic acidBoronic AcidsContrast Mediagadolinium complexesMRI contrast enhancementphenylboronic acidsialic acidtumor targeting

Identifiers

PMID33808910
PMCPMC8003780
OpenAlexW3137210950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.